Schizophrenia; recent cognitive and treatment approaches using induced pluripotent stem cells
International Clinical Neuroscience Journal,
Vol. 7 No. 4 (2020),
28 September 2020
One of the most severe mental disorder which leads to a disturbance in the percipience of reality is named schizophrenia. Schizophrenia is a combination of hallucinations, delusions, and mental disorders, that the severity of them impairs normal thinking and behavior, and in general the inability to perform daily activities. Behavioral, intellectual, and emotional disorders indicate the widespread impact of Schizophrenia on various aspects of mental health. The signs and symptoms of schizophrenia are very varied, although delusions, hallucinations, or disorganized speech are included in common symptoms. Dopamine has been the main subject of much research on schizophrenia for decades. Molecular neuroimaging studies to explore the Dopamine System (DA system) in vivo have revealed that schizophrenia is first associated with a defect in the striatum and then with a defect in extrastriatal regions with centralizing on Cortex and midbrain. Also, the Gamma-Aminobutyric acid (GABA) mRNA dysregulation and Neuroinflammatory mechanisms can be effective in schizophrenia. Various medications such as antipsychotic drugs are used to the aim of treating this disease but they can just decline or improve the positive symptoms. Modeling of neurodevelopment and synaptic connection defects by induced human pluripotent stem cells have made appropriate circumstances to the elimination of schizophrenia treatment barriers. With the development of cell therapies and the usage of induced pluripotent stem cells, there is a hope that the negative symptoms can be improved by this approach.
- iPS cells
- DA hypothesis
How to Cite
Owen MJ, O'Donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. The British journal of psychiatry. 2011;198(3):173-5.
Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®): American Psychiatric Pub; 2013.
Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. The American journal of psychiatry. 1991.
Cho SJ, Kim J, Kang YJ, Lee SY, Seo HY, Park JE, et al. Annual Prevalence and Incidence of Schizophrenia and Similar Psychotic Disorders in the Republic of Korea: A National Health Insurance Data-Based Study. Psychiatry Investigation. 2020;17(1):61.
Rajji T, Ismail Z, Mulsant B. Age at onset and cognition in schizophrenia: meta-analysis. The British Journal of Psychiatry. 2009;195(4):286-93.
Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clinical neuropharmacology. 2003;26(1):8-11.
Edition F. Diagnostic and statistical manual of mental disorders. Am Psychiatric Assoc. 2013.
Carpenter Jr W. Buchanan RW. Schizophrenia. N Engl J Med. 1994;330:681-90.
Hannerz H, Borgå P, Borritz M. Life expectancies for individuals with psychiatric diagnoses. Public health. 2001;115(5):328-37.
Woodward TS, Moritz S, Cuttler C, Whitman JC. The contribution of a cognitive bias against disconfirmatory evidence (BADE) to delusions in schizophrenia. Journal of Clinical and Experimental Neuropsychology. 2006;28(4):605-17.
ENT R. Hallucination; Defination, Types, Causes, Symptoms, Diagnosis, Treatment, Self care, Home Remedies.
Kuperberg G, Caplan D. Language dysfunction in schizophrenia. Neuropsychiatry Lippincott Williams and Wilkins, Philadelphia. 2003:444-66.
Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Archives of general psychiatry. 1982;39(7):784-8.
Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14-24.
Marder SR, Davidson M, Zaragoza S, Kott A, Khan A, Wang X, et al. Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements. Schizophrenia Bulletin Open. 2020;1(1):sgz001.
Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. The Lancet Psychiatry. 2018;5(8):664-77.
Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? Journal of translational neuroscience. 2016;1(1):37.
Zamanpoor M. Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatric Genetics. 2020;30(1):1-9.
Schmidt-Kastner R, Guloksuz S, Kietzmann T, Van Os J, Rutten BP. Analysis of GWAS-derived schizophrenia genes for links to ischemia-hypoxia response of the brain. Frontiers in Psychiatry. 2020;11.
Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, et al. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register. Biological psychiatry. 2018;83(6):492-8.
Malavia TA, Chaparala S, Wood J, Chowdari K, Prasad KM, McClain L, et al. Generating testable hypotheses for schizophrenia and rheumatoid arthritis pathogenesis by integrating epidemiological, genomic, and protein interaction data. NPJ schizophrenia. 2017;3(1):1-10.
Caspi A, Moffitt TE. Gene–environment interactions in psychiatry: joining forces with neuroscience. Nature Reviews Neuroscience. 2006;7(7):583-90.
Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophrenia bulletin. 1976;2(1):19.
Zhang Y, Yang R, Cai X. Frequency-specific alternations in the moment-to-moment BOLD signals variability in schizophrenia. Brain Imaging and Behavior. 2020:1-8.
Lodge DJ, Grace AA. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends in pharmacological sciences. 2011;32(9):507-13.
McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends in neurosciences. 2019;42(3):205-20.
Slifstein M, Van De Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA psychiatry. 2015;72(4):316-24.
Schoonover KE, Dienel SJ, Lewis DA. Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: Insights for rational biomarker development. Biomarkers in Neuropsychiatry. 2020:100015.
Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. American Journal of Psychiatry. 2002;159(7):1165-73.
Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajós M. Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery. 2008;7(1):68-83.
Radhakrishnan R, Kaser M, Guloksuz S. The link between the immune system, environment, and psychosis. Schizophrenia bulletin. 2017;43(4):693-7.
Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry and clinical neurosciences. 2014;68(1):21-36.
Watkins CC, Andrews SR. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophrenia research. 2016;176(1):14-22.
Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Annals of the New York Academy of Sciences. 2012;1262(1):56-66.
Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutrition reviews. 2007;65(suppl_3):S194-S202.
Khandaker GM, Zimbron J, Lewis G, Jones P. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychological medicine. 2013;43(2):239.
Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophrenia bulletin. 2011;37(2):284-90.
Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R, Mankoo BS, et al. Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32. 2, 5q33. 2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23. 3-24 and 20q12. 1-11.23. The American Journal of Human Genetics. 2001;68(3):661-73.
Corvin A, Morris DW. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biological psychiatry. 2014;75(4):276-83.
Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biological psychiatry. 2013;73(10):951-66.
Tsuang MT, Bar JL, Stone WS, Faraone SV. Gene-environment interactions in mental disorders. World psychiatry. 2004;3(2):73.
Ferentinos P, Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Current opinion in psychiatry. 2012;25(5):381-90.
Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, et al. GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Molecular psychiatry. 2011;16(11):1117-29.
Børglum A, Demontis D, Grove J, Pallesen J, Hollegaard MV, Pedersen C, et al. Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. Molecular psychiatry. 2014;19(3):325-33.
Sundararajan T, Manzardo AM, Butler MG. Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. Gene. 2018;641:25-34.
Freudenreich O. Psychotic disorders: Springer; 2020.
Cacabelos R. Pharmacogenomics of cognitive dysfunction and neuropsychiatric disorders in dementia. International Journal of Molecular Sciences. 2020;21(9):3059.
Molnar E, Isaac JT. Developmental and activity dependent regulation of ionotropic glutamate receptors at synapses. TheScientificWorldJOURNAL. 2002;2.
Fénelon K, Mukai J, Xu B, Hsu P-K, Drew LJ, Karayiorgou M, et al. Deficiency of Dgcr8, a gene disrupted by the 22q11. 2 microdeletion, results in altered short-term plasticity in the prefrontal cortex. Proceedings of the National Academy of Sciences. 2011;108(11):4447-52.
Sigurdsson T, Stark KL, Karayiorgou M, Gogos JA, Gordon JA. Impaired hippocampal–prefrontal synchrony in a genetic mouse model of schizophrenia. Nature. 2010;464(7289):763-7.
Topol A, English J, Flaherty E, Rajarajan P, Hartley B, Gupta S, et al. Increased abundance of translation machinery in stem cell–derived neural progenitor cells from four schizophrenia patients. Translational psychiatry. 2015;5(10):e662-e.
Liu YN, Lu SY, Yao J. Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia. Psychiatry and Clinical Neurosciences. 2017;71(9):579-99.
Miyamoto S, Duncan G, Marx C, Lieberman J. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular psychiatry. 2005;10(1):79-104.
Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS drugs.
Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatric Disease and Treatment. 2019;15:1525.
Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Advances in Psychiatric treatment. 2005;11(2):125-32.
Malhotra N, Kulhara P, Chakrabarti S, Grover S. Lifestyle related factors & impact of metabolic syndrome on quality of life, level of functioning & self-esteem in patients with bipolar disorder & schizophrenia. The Indian journal of medical research. 2016;143(4):434.
Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophrenia research and treatment. 2012;2012.
Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473(7346):221-5.
Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell stem cell. 2007;1(1):39-49.
Buecker C, Chen H-H, Polo JM, Daheron L, Bu L, Barakat TS, et al. A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells. Cell stem cell. 2010;6(6):535-46.
Feng B, Ng J-H, Heng J-CD, Ng H-H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell stem cell. 2009;4(4):301-12.
Brennand KJ, Landek-Salgado MA, Sawa A. Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells. Biological psychiatry. 2014;75(12):936-44.
Pruessner JC, Champagne F, Meaney MJ, Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C] raclopride. Journal of Neuroscience. 2004;24(11):2825-31.
Biechele TL, Camp ND, Fass DM, Kulikauskas RM, Robin NC, White BD, et al. Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma. Chemistry & biology. 2010;17(11):1177-82.
Hook V, Brennand KJ, Kim Y, Toneff T, Funkelstein L, Lee KC, et al. Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons. Stem cell reports. 2014;3(4):531-8.
Korpi ER, Kleinman JE, Goodman SI, Wyatt RJ. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry research. 1987;22(4):291-301.
Wang Z, Neylan TC, Mueller SG, Lenoci M, Truran D, Marmar CR, et al. Magnetic resonance imaging of hippocampal subfields in posttraumatic stress disorder. Archives of general psychiatry. 2010;67(3):296-303.
Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Archives of general psychiatry. 2000;57(1):65-73.
Yu DX, Di Giorgio FP, Yao J, Marchetto MC, Brennand K, Wright R, et al. Modeling hippocampal neurogenesis using human pluripotent stem cells. Stem cell reports. 2014;2(3):295-310.
Chiang C, Su Y, Wen Z, Yoritomo N, Ross CA, Margolis RL, et al. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Molecular psychiatry.
Huang H-P, Chen P-H, Yu C-Y, Chuang C-Y, Stone L, Hsiao W-C, et al. Epithelial cell adhesion molecule (EpCAM) complex proteins promote transcription factor-mediated pluripotency reprogramming. Journal of Biological Chemistry. 2011;286(38):33520-32.
Tran NN, Ladran IG, Brennand KJ. Modeling Schizophrenia Using induced pluripotent Stem cell–Derived and Fibroblast-induced neurons. Schizophrenia bulletin. 2013;39(1):4-10.
Rajarajan P, Borrman T, Liao W, Schrode N, Flaherty E, Casiño C, et al. Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk. Science. 2018;362(6420).
MacDonald AB. Alzheimer’s neuroborreliosis with trans-synaptic spread of infection and neurofibrillary tangles derived from intraneuronal spirochetes. Medical hypotheses. 2007;68(4):822-5.
Donegan JJ, Tyson JA, Branch SY, Beckstead MJ, Anderson SA, Lodge DJ. Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model. Molecular psychiatry. 2017;22(10):1492-501.
Donegan JJ, Boley AM, Lodge DJ. Embryonic stem cell transplants as a therapeutic strategy in a rodent model of autism. Neuropsychopharmacology. 2018;43(8):1789-98.
Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009;461(7262):402-6.
Inan M, Welagen J, Anderson SA. Spatial and temporal bias in the mitotic origins of somatostatin-and parvalbumin-expressing interneuron subgroups and the chandelier subtype in the medial ganglionic eminence. Cerebral cortex. 2012;22(4):820-7.
Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010;143(4):527-39.
Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell stem cell. 2007;1(1):55-70.
Lange N, Giedd JN, Castellanos FX, Vaituzis AC, Rapoport JL. Variability of human brain structure size: ages 4–20 years. Psychiatry Research: Neuroimaging. 1997;74(1):1-12.
Brennand KJ, Gage FH. Concise review: the promise of human-induced pluripotent stem cell‐based studies of schizophrenia. Stem cells. 2011;29(12):1915-22.
- Abstract Viewed: 156 times
- PDF Downloaded: 235 times